ProfileGDS5678 / 1416317_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 44% 40% 45% 44% 40% 43% 43% 63% 45% 45% 50% 44% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.031843
GSM967853U87-EV human glioblastoma xenograft - Control 23.0237644
GSM967854U87-EV human glioblastoma xenograft - Control 32.9273240
GSM967855U87-EV human glioblastoma xenograft - Control 42.997145
GSM967856U87-EV human glioblastoma xenograft - Control 52.9833344
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0161740
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0510743
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9816943
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7857963
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0219145
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0445345
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1685950
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0214444
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0271844